Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis

M. Amin, K. Darji, D.J. No, J.J. Wu
  • Journal of the European Academy of Dermatology and Venereology, July 2017, Wiley
  • DOI: 10.1111/jdv.14451
The author haven't finished explaining this publicationThe author haven't finished explaining this publication

The following have contributed to this page: Dr Jashin J Wu

In partnership with: